Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) shares fell 1% on Wednesday . The company traded as low as C$4.05 and last traded at C$4.14. Approximately 9,455 shares traded hands during trading, an increase of 28% from the average session volume of 7,410 shares. The stock had previously closed at C$4.18.
Eupraxia Pharmaceuticals Stock Performance
The company has a fifty day moving average price of C$3.45 and a 200-day moving average price of C$3.09.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
See Also
- Five stocks we like better than Eupraxia Pharmaceuticals
- Are Penny Stocks a Good Fit for Your Portfolio?
- FedEx Delivers Another Crushing Blow to Its Stock Price
- How to Profit From Growth Investing
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- 3 Tickers Leading a Meme Stock Revival
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
